British drugmaker GlaxoSmithKline (GSK) has agreed to pay up to $2.2 billion to settle lawsuits in the US over its heartburn drug Zantac.
The settlement covers about 80,000 cases alleging that Zantac, known generically as ranitidine, caused cancer.
GSK maintains that there is no evidence linking Zantac to cancer but has not admitted liability in the settlements.
The company expects to recognize a charge of £1.8 billion in its third-quarter results related to the settlement.
